PerkinElmer and IDBS Announce Software Collaboration for Drug Discovery Research
News Jan 08, 2009
IDBS has announced a collaboration with PerkinElmer, Inc. at the 6th Annual High Content Analysis Conference in San Francisco.
The collaboration will be focused on improving data analysis and interpretation of High Content Screening (HCS), an enabling technology in the search for key cellular markers associated with human health and disease.
The collaboration features the integration of PerkinElmer’s Columbus™ image data management system for HCS with IDBS’s ActivityBase XE screening data management software.
The collaboration will provide researchers with a unified interface to access both Columbus’s image data storage capabilities and ActivityBase XE’s screening data analysis and interpretation features, to enable compelling exploratory outcomes in HCS and cellular analysis.
“The future of High Content Screening lies in an increased synergy between technologies that integrate vast image content with large compound sets, to generate actionable research data,” said Richard M. Eglen, Ph.D., president, Bio-discovery, PerkinElmer. “We feel this collaboration with IDBS is a timely and highly promising advance in giving researchers access to greater insights into the cell-based mechanisms of disease, as well as development of novel therapies based on greater understanding of the origins of diseases.”
Neil Kipling, CEO of IDBS, said “ActivityBase XE maintains IDBS’s leading position in data management for the global drug discovery industry, offering innovation and scalable functionality to screening groups worldwide. This new relationship with PerkinElmer provides scientists with the high performance data management tools necessary to maximize the promise which this technical innovation presents.”
PerkinElmer’s Columbus software is a flexible solution for high volume image storage and management. Designed as a partner product for the Opera™ system, PerkinElmer's confocal microplate imaging reader, the software has the added benefit of full compatibility with a wide range of image file formats.
IDBS’s ActivityBase XE delivers ultra high performance data analysis, flexible data visualization/interpretation and storage in one working environment. The new features in ActivityBase XE enable users to analyze rich, multivariant data, perform curve fitting and complex statistics within each well of a MTS, HTS or uHTS experiment.
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE